The first irreversible BTK kinase inhibitor PCI-32765, which has demonstrated the proof-of-concept for the anti-arthritis efficacy by direct inhibition of BTK kinase, also bears potent activities against BLK, BMX, EGFR, Her2, ITK, JAK3, TEC and others9–11. This evidence concerns the gene BLK and arthritic joint disease.